http://www.equities.com/news/headline-story?dt=2012-09-03&val=440525&cat=hcare
NEWARK, Calif., Sept. 3, 2012 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced that interim six-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human